Clinical Pearls and Future Directions of Cervical Cancer Treatment
Ritu Salani, MD, offers advice for community oncologists treating patients with cervical cancer and discusses the future directions of the treatment landscape.
Second-Line Treatment Options for Recurrent or Metastatic Cervical Cancer
A gynecologic oncologist discusses second-line treatment options for patients with recurrent or metastatic cervical cancer, and provides insights on toxicity management.
Metastatic Cervical Cancer: First-Line Treatment Options
An overview of first-line treatment options and immune checkpoint inhibitors in metastatic cervical cancer.
Current Role of Biomarker Testing in Cervical Cancer
Ritu Salani, MD, offers clinical insights on the role of biomarker testing in treating cervical cancer.
Cervical Cancer: Classification, Staging, and Prevention
An expert gynecologic oncologist reviews the biology of cervical cancer and discusses how HPV vaccination is increasingly playing a role in prevention.
Patient Profile: A 50-Year-Old Woman With Cervical Cancer
Ritu Salani, MD, presents the case of a patient with cervical cancer and describes the typical disease presentation and risk factors.
Future Directions in the Management of Endometrial Cancer
Closing out her discussion on novel therapeutics in endometrial cancer, Ritu Salani, MD, MBA, shares excitement for ongoing evolutions within the treatment landscape.
Antibody Drug Conjugate Data in Endometrial Cancer: TROPiCS-03
Expert Ritu Salani, MD, MBA, reviews data from TROPiCS-03 and considers the potential role for antibody drug conjugates in patients with advanced endometrial cancer.
Adjuvant IO Strategies in Endometrial Cancer: RAINBO and GY020
A brief review of clinical trial data from RAINBO and GY020, which tested adjuvant immunotherapy following radiation in patients with endometrial cancer.
Single-Agent IO Therapy in Advanced Endometrial Cancer: PHAEDRA and DOMENICA
Focused discussion on single-agent immunotherapy in patients with advanced endometrial cancer following data from the PHAEDRA and DOMENICA clinical trials.
Combination IO Strategies in Advanced Endometrial Cancer: RUBY and GY018
Expert perspectives on the RUBY and GY018 trials, which tested dostarlimab and pembrolizumab, respectively, in combination with chemotherapy in patients with advanced or recurrent endometrial cancer.
Recurrent Endometrial Cancer: An Evolving Treatment Landscape
Closing out her discussion on the management of recurrent endometrial cancer, Ritu Salani, MD, MBA, shares clinical pearls amidst the shifting treatment paradigm.
Immune Checkpoint Inhibitors in Recurrent Endometrial Cancer: Clinical Trial Data
A focused review of clinical trial data that inform the use of immune checkpoint inhibition in the setting of recurrent endometrial cancer.
Endometrial Cancer: Factors in Selecting First- and Second-Line Therapy
An expert gynecologic oncologist shares her perspective on treatment options available to patients in the first- and second-line settings of endometrial cancer.
Patient Case: A 64-Year-Old Woman With Recurrent Endometrial Cancer
Opening her discussion on a patient case of recurrent endometrial cancer, Ritu Salani, MD, MBA, highlights the evolving role of molecular testing in this setting.
2 Clarke Drive Cranbury, NJ 08512